The Flordis seed to patient journey:
1. Consistent raw materials
Wherever possible our cultivation methods observe Good Agricultural Practices (GAP) which involves working closely with farmers and other partners. There is more to the seed-to-patient process, however, including selection of the exact species and standardisation of propagation, cultivation and harvesting. These controls play a large part in contributing to raw materials with a consistent phytochemical profile.
2. Consistent extraction and manufacture of finished product
The seed-to-patient process demands more than the observation of Good Manufacturing Practice (GMP). Standardisation of all inputs and processes is essential to help ensure product consistency from one batch to the next, often referred to as batch to batch consistency. A series of strict controls are applied to manufacturing processes including solvents used and extraction methods, through to packaging, storage and transportation of finished goods.
3. Clinical research
The final stage in the seed-to-patient process is to conduct research and clinical trials to substantiate safety and efficacy of finished products. Clinical study results are validated by publication in respected peer-reviewed scientific journals. Our batch to batch consistency means that the specific medicine tested in clinical trials is the same medicine used in Flordis products.
By applying this high standard, Flordis delivers a specialised portfolio of world class natural medicines that are well tolerated and effective. The result is more reliable health outcomes. This is one of the reasons why Flordis natural medicines are recommended to millions of people worldwide – and why you can feel confident that you are taking a quality natural medicine.